Ramzi Fattouh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ramzi Fattouh has a total of 360 co-authors. Here are the top co-authors by number of shared publications:
Manel Jordana
Department of Pathology and Molecular Medicine, Centre for Gene Therapeutics, Division of Respiratory Diseases and Allergy, McMaster University, Hamilton, ON, Canada
18 shared publicationsSusanna Goncharova
McMaster Immunology Research Centre (MIRC), Department of Pathology and Molecular Medicine, and Department of Medicine, McMaster University, Hamilton, Ontario L8N 3Z5, Canada
12 shared publications- Martin R. Stampfli
McMaster Immunology Research Centre, McMaster University, Hamilton, Canada
8 shared publications Anthony J. Coyle
Department of Pathology and Molecular Medicine, McMaster Immunology Research Centre, Hamilton, Ontario, Canada ; Pfizer, Cambridge, Massachusetts, United States of America
7 shared publicationsDavid Alvarez
Division of Respiratory Diseases and Allergy, Centre for Gene Therapeutics, Department of Pathology and Molecular Medicine, McMaster University , Hamilton, Ontario
6 shared publicationsTina D. Walker
McMaster Immunology Research Centre (MIRC), Department of Pathology and Molecular Medicine, and Department of Medicine, McMaster University, Hamilton, Ontario L8N 3Z5, Canada
6 shared publications
Latest Publications
- Open Access
- 18 July 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (8) , e0044125
Performance evaluation of the NG-TEST CARBA 5 and Genobio K.N.I.V.O. detection K-Set lateral flow assays for the detection of carbapenemases
Infection with carbapenemase-producing organisms (CPOs) is associated with significant morbidity and mortality among hospitalized patients. Thus, the identification of CPOs is an important function of clinical microbiology laboratories. This study evaluates the performance of two lateral flow assays (LFAs), the NG-Test CARBA 5 (CARBA 5) and Genobio K.N.I.V.O. Detection K-Set (Genobio), for the detection of carbapenemases using well-characterized clinical and reference isolates of gram-negative bacterial species. Both LFAs are designed to detect KPC, NDM, VIM, IMP, and OXA-48-like carbapenemases from bacterial growth within 15 minutes. In total, 152 isolates were tested: 10 Acinetobacter baumannii , 12 Pseudomonas aeruginosa , and 130 from various Enterobacterales . Among these, 132 harbored a carbapenemase, and 20 were carbapenemase-negative. Additionally, LFAs were scored for background color and test indicator line intensity. For Enterobacterales , the CARBA 5 had an overall positive agreement of 100%, while Genobio had a positive agreement of 98.5% because of a failure to detect IMP in a Klebsiella pneumoniae isolate and false cross-reactivity for NDM and OXA-48 in a KPC-positive Morganella morganii . Both LFAs demonstrated a positive agreement of 100% among carbapenemase-producing A. baumannii and P. aeruginosa isolates. Neither LFA falsely detected carbapenemases among carbapenemase-negative isolates, nor was any positivity observed among isolates that carried an off-target carbapenemase. In terms of test indicator line intensity, both LFAs showed comparable performance; however, the Genobio LFA displayed a propensity for higher background signal. Overall, both LFAs demonstrated very good performance in detecting select carbapenemases and offered a fast turnaround time, straightforward interpretation, and minimal hands-on time. IMPORTANCE: This study contributes to the field by providing additional information on the performance of two commercial tests, known generally as lateral flow assays (LFA). These assays are used to identify a family of proteins, called carbapenemases, that cause antibiotic resistance and greatly limit the choices of antibiotics that can be used to treat infection. Our study evaluates the performance of two LFAs in a variety of bacteria, including some that are commonly studied (members of the Enterobacterales ) as well as others where less test performance information is available ( Pseudomonas aeruginosa and Acinetobacter baumannii ). Our findings show that the LFAs provide a fast turnaround time and require minimal hands-on time in comparison to other tests. In addition, we provide information about practical factors that could negatively affect how the results are interpreted in busy clinical laboratories, such as the ease of “seeing” and interpreting the results.
- 18 July 2025
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 13 (8) , e0044125
Open AccessPerformance evaluation of the NG-TEST CARBA 5 and Genobio K.N.I.V.O. detection K-Set lateral flow assays for the detection of carbapenemases
Infection with carbapenemase-producing organisms (CPOs) is associated with significant morbidity and mortality among hospitalized patients. Thus, the identification of CPOs is an important function of clinical microbiology laboratories. This study evaluates the performance of two lateral flow assays (LFAs), the NG-Test CARBA 5 (CARBA 5) and Genobio K.N.I.V.O. Detection K-Set (Genobio), for the detection of carbapenemases using well-characterized clinical and reference isolates of gram-negative bacterial species. Both LFAs are designed to detect KPC, NDM, VIM, IMP, and OXA-48-like carbapenemases from bacterial growth within 15 minutes. In total, 152 isolates were tested: 10 Acinetobacter baumannii , 12 Pseudomonas aeruginosa , and 130 from various Enterobacterales . Among these, 132 harbored a carbapenemase, and 20 were carbapenemase-negative. Additionally, LFAs were scored for background color and test indicator line intensity. For Enterobacterales , the CARBA 5 had an overall positive agreement of 100%, while Genobio had a positive agreement of 98.5% because of a failure to detect IMP in a Klebsiella pneumoniae isolate and false cross-reactivity for NDM and OXA-48 in a KPC-positive Morganella morganii . Both LFAs demonstrated a positive agreement of 100% among carbapenemase-producing A. baumannii and P. aeruginosa isolates. Neither LFA falsely detected carbapenemases among carbapenemase-negative isolates, nor was any positivity observed among isolates that carried an off-target carbapenemase. In terms of test indicator line intensity, both LFAs showed comparable performance; however, the Genobio LFA displayed a propensity for higher background signal. Overall, both LFAs demonstrated very good performance in detecting select carbapenemases and offered a fast turnaround time, straightforward interpretation, and minimal hands-on time. IMPORTANCE: This study contributes to the field by providing additional information on the performance of two commercial tests, known generally as lateral flow assays (LFA). These assays are used to identify a family of proteins, called carbapenemases, that cause antibiotic resistance and greatly limit the choices of antibiotics that can be used to treat infection. Our study evaluates the performance of two LFAs in a variety of bacteria, including some that are commonly studied (members of the Enterobacterales ) as well as others where less test performance information is available ( Pseudomonas aeruginosa and Acinetobacter baumannii ). Our findings show that the LFAs provide a fast turnaround time and require minimal hands-on time in comparison to other tests. In addition, we provide information about practical factors that could negatively affect how the results are interpreted in busy clinical laboratories, such as the ease of “seeing” and interpreting the results.
- Open Access
- 13 March 2023
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 44 (11) , 1829-1833
Coronavirus disease 2019 (COVID-19) outbreak on an in-patient medical unit associated with unrecognized exposures in common areas—Epidemiological and whole-genome sequencing investigation
Objective: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) hospital outbreaks have been common and devastating during the coronavirus disease 2019 (COVID-19) pandemic. Understanding SARS-CoV-2 transmission in these environments is critical for preventing and managing outbreaks. Design: Outbreak investigation through epidemiological mapping and whole-genome sequencing phylogeny. Setting: Hospital in-patient medical unit outbreak in Toronto, Canada, from November 2020 to January 2021. Participants: The outbreak involved 8 patients and 10 staff and was associated with 3 patient deaths. Results: Patients being cared for in geriatric chairs at the nursing station were at high risk for both acquiring and transmitting SARS-CoV-2 to other patients and staff. Furthermore, given the informal nature of these transmissions, they were not initially recognized, which led to further transmission and missing the opportunity for preventative COVID-19 therapies. Conclusions: During outbreak prevention and management, the risk of informal patient care settings, such as geriatric chairs, should be considered. During high-risk periods or during outbreaks, efforts should be made to care for patients in their rooms when possible.
- 13 March 2023
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 44 (11) , 1829-1833
Open AccessCoronavirus disease 2019 (COVID-19) outbreak on an in-patient medical unit associated with unrecognized exposures in common areas—Epidemiological and whole-genome sequencing investigation
Objective: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) hospital outbreaks have been common and devastating during the coronavirus disease 2019 (COVID-19) pandemic. Understanding SARS-CoV-2 transmission in these environments is critical for preventing and managing outbreaks. Design: Outbreak investigation through epidemiological mapping and whole-genome sequencing phylogeny. Setting: Hospital in-patient medical unit outbreak in Toronto, Canada, from November 2020 to January 2021. Participants: The outbreak involved 8 patients and 10 staff and was associated with 3 patient deaths. Results: Patients being cared for in geriatric chairs at the nursing station were at high risk for both acquiring and transmitting SARS-CoV-2 to other patients and staff. Furthermore, given the informal nature of these transmissions, they were not initially recognized, which led to further transmission and missing the opportunity for preventative COVID-19 therapies. Conclusions: During outbreak prevention and management, the risk of informal patient care settings, such as geriatric chairs, should be considered. During high-risk periods or during outbreaks, efforts should be made to care for patients in their rooms when possible.
- Open Access
- 9 January 2023
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 3 (1) , e7
Detection of SARS-CoV-2 from combined nasal/rectal swabs
- 9 January 2023
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 3 (1) , e7
Open AccessDetection of SARS-CoV-2 from combined nasal/rectal swabs
- 21 December 2022
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 25 (3) , 133-142
A Novel Approach to Detect IDH Point Mutations in Gliomas Using Nanopore Sequencing
- 21 December 2022
- Published by Elsevier in The Journal of Molecular Diagnostics
- Vol. 25 (3) , 133-142
A Novel Approach to Detect IDH Point Mutations in Gliomas Using Nanopore Sequencing
- 16 November 2022
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 60 (11) , e0066522
A Prolonged Outbreak of Human Adenovirus A31 (HAdV-A31) Infection on a Pediatric Hematopoietic Stem Cell Transplantation Ward with Whole Genome Sequencing Evidence of International Linkages
A surge in hematopoietic stem cell transplantation (HSCT) human adenovirus A31 (HAdV-A31) infections was initially observed in late 2014/2015 at SickKids (SK) Hospital, Toronto, Canada. In response, enhanced laboratory monitoring for all adenovirus infections was conducted.
- 16 November 2022
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 60 (11) , e0066522
A Prolonged Outbreak of Human Adenovirus A31 (HAdV-A31) Infection on a Pediatric Hematopoietic Stem Cell Transplantation Ward with Whole Genome Sequencing Evidence of International Linkages
A surge in hematopoietic stem cell transplantation (HSCT) human adenovirus A31 (HAdV-A31) infections was initially observed in late 2014/2015 at SickKids (SK) Hospital, Toronto, Canada. In response, enhanced laboratory monitoring for all adenovirus infections was conducted.
- Open Access
- 19 August 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1
Author Correction: Emergence of a mutation in the nucleocapsid gene of SARS-CoV-2 interferes with PCR detection in Canada
- 19 August 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1
Open AccessAuthor Correction: Emergence of a mutation in the nucleocapsid gene of SARS-CoV-2 interferes with PCR detection in Canada
- Open Access
- 27 June 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-7
Emergence of a mutation in the nucleocapsid gene of SARS-CoV-2 interferes with PCR detection in Canada
The emergence of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) was met with rapid development of robust molecular-based detection assays. Many SARS-CoV-2 molecular tests target multiple genetic regions of the virus to maximize detection and protect against diagnostic escape. Despite the relatively moderate mutational rate of SARS-CoV-2, numerous mutations with known negative impact on diagnostic assays have been identified. In early 2021, we identified four samples positive for SARS-CoV-2 with a nucleocapsid (N) gene drop out on Cepheid Xpert® Xpress SARS-CoV-2 assay. Sequencing revealed a single common mutation in the N gene C29200T. Spatiotemporal analysis showed that the mutation was found in at least six different Canadian provinces from May 2020 until May 2021. Phylogenetic analysis showed that this mutation arose multiple times in Canadian samples and is present in six different variants of interest and of concern. The Cepheid testing platform is commonly used in Canada including in remote regions. As such, the existence of N gene mutation dropouts required further investigation. While commercial SARS-CoV-2 molecular detection assays have contributed immensely to the response effort, many vendors are reluctant to make primer/probe sequences publicly available. Proprietary primer/probe sequences create diagnostic ‘blind spots’ for global SARS-CoV-2 sequence monitoring and limits the ability to detect and track the presence and prevalence of diagnostic escape mutations. We hope that our industry partners will seriously consider making primer/probe sequences available, so that diagnostic escape mutants can be identified promptly and responded to appropriately to maintain diagnostic accuracy.
- 27 June 2022
- Published by Springer Nature in Scientific Reports
- Vol. 12 (1) , 1-7
Open AccessEmergence of a mutation in the nucleocapsid gene of SARS-CoV-2 interferes with PCR detection in Canada
The emergence of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) was met with rapid development of robust molecular-based detection assays. Many SARS-CoV-2 molecular tests target multiple genetic regions of the virus to maximize detection and protect against diagnostic escape. Despite the relatively moderate mutational rate of SARS-CoV-2, numerous mutations with known negative impact on diagnostic assays have been identified. In early 2021, we identified four samples positive for SARS-CoV-2 with a nucleocapsid (N) gene drop out on Cepheid Xpert® Xpress SARS-CoV-2 assay. Sequencing revealed a single common mutation in the N gene C29200T. Spatiotemporal analysis showed that the mutation was found in at least six different Canadian provinces from May 2020 until May 2021. Phylogenetic analysis showed that this mutation arose multiple times in Canadian samples and is present in six different variants of interest and of concern. The Cepheid testing platform is commonly used in Canada including in remote regions. As such, the existence of N gene mutation dropouts required further investigation. While commercial SARS-CoV-2 molecular detection assays have contributed immensely to the response effort, many vendors are reluctant to make primer/probe sequences publicly available. Proprietary primer/probe sequences create diagnostic ‘blind spots’ for global SARS-CoV-2 sequence monitoring and limits the ability to detect and track the presence and prevalence of diagnostic escape mutations. We hope that our industry partners will seriously consider making primer/probe sequences available, so that diagnostic escape mutants can be identified promptly and responded to appropriately to maintain diagnostic accuracy.
- 1 December 2021
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 56 (6) , e174-e176
Cytomegalovirus anterior uveitis in consecutive eyes with hypertensive uveitis: a tertiary care centre experience
- 1 December 2021
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 56 (6) , e174-e176
Cytomegalovirus anterior uveitis in consecutive eyes with hypertensive uveitis: a tertiary care centre experience
- 1 November 2020
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 76 (5) , 690-695.e1
COVID-19 Outbreak in an Urban Hemodialysis Unit
- 1 November 2020
- Published by Elsevier in American Journal of Kidney Diseases
- Vol. 76 (5) , 690-695.e1
COVID-19 Outbreak in an Urban Hemodialysis Unit
- Open Access
- 1 July 2020
- Published by Elsevier in Journal of Clinical Virology
- Vol. 128, 104433
Real-time PCR-based SARS-CoV-2 detection in Canadian laboratories
- 1 July 2020
- Published by Elsevier in Journal of Clinical Virology
- Vol. 128, 104433
Open AccessReal-time PCR-based SARS-CoV-2 detection in Canadian laboratories